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Axial SpA (axSpA) can affect diverse elements of an individual’s life. The areas affected can be much more
wide-ranging than the historical medical model of SpA, causing increased disease activity (pain and
stiffness) and disability (reduced range of movement and physical function). A more holistic view of the
individual results in the realization that many other areas of life can be adversely affected by axSpA, from
the ability to work effectively and function socially, to effects on quality of life and the onset of worsening
fatigue or mood disturbance. A good understanding of these areas outside the medical model allows for
an improved understanding of the overall life impact of axSpA. This highlights the importance of under-
standing how to measure these elements of life using patient-reported outcome measures that can truly
reflect an individual’s experience of axSpA. These measures can then provide a better insight into the
risks and benefits of interventions and medications used to treat axSpA.
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Rheumatology key messages
. The impact of axial SpA is much wider than physical function, pain and disease activity.
. Axial SpA may affect work, mood, fatigue and quality of life.
. Interventions considered for axial SpA should include a spectrum from psychological counselling to biological.
Introduction
Important advances in the diagnosis and classification of
SpA over the past 10 years particularly include the dem-
onstration of spinal inflammation using MRI in the absence
of radiographic evidence of change [1, 2]. The diagnosis of
axial SpA (axSpA) reflects patients within a spectrum of
disease presentations and investigations and ranges from
those with radiographic sacroiliac changes (previously
referred to as AS) to those with only clinical features sug-
gesting axial inflammation. Patients with axSpA without
radiographic evidence of sacroiliitis can now be classified
as having non-radiographic axSpA, which does not
appear to differ significantly from radiographic axSpA
(synonymous with AS) in terms of the main clinical mani-
festations, disease activity, pain and effect of biologics
[35]. Although non-radiographic axSpA has less inflam-
mation (lower CRP levels and less spinal inflammation on
MRI) and less impairment in spinal mobility compared with
AS, the two ends of the spectrum are associated with a
similar burden in terms of physical function, mood disturb-
ance, work impact and quality of life impairment [6].
Before the introduction of the Assessment of
SpondyloArthritis international Society (ASAS) criteria,
the adult prevalence of AS was estimated to be between
0.1 and 1.4%. It varies with geographical region (reflecting
varying prevalence of HLA-B27), with the highest rates
found in northern Europeans and indigenous North
Americans [79]. European estimates include a preva-
lence of 0.9% in Germany [8] and 1.11.4% in northern
Norway [9], which are markedly higher than estimates in
non-Caucasian populations such as Turkey at 0.25% [10]
or China at 0.11% [11].
The more inclusive classification criteria will have a con-
siderable impact on the increasing prevalence of SpA, be-
cause many patients with previously unclassifiable axSpA
can now be identified as having SpA [1]. This has
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socioeconomic implications for the overall burden of dis-
ease. AxSpA occurs in young adults at the peak of their
productive lifespan [2] and is associated with a consider-
able burden in terms of restrictions in activities of daily
living [12, 13] and reduction in health-related quality of
life (HRQoL) [13], work productivity and rates of employ-
ment [7, 14, 15]. Because axSpA usually starts before
45 years of age, the effect of the disease on different as-
pects of life (career, family and social life) is of consider-
able duration.
Importance of reduction in work
productivity on individuals and society
Reduction in work productivity is an important component
of the indirect costs of SpA, which are typically calculated
in terms of absenteeism and presenteeism using the Work
Productivity and Activity Impairment Questionnaire in AS
[16]. Absenteeism is defined as the quantity of potentially
disease-related sick leave, whereas presenteeism is defined
as patient-reported reduced productivity at work [16].
In a UK study of 612 AS patients [15], employment rates
were 14% lower than the UK national average, with 39.5%
of patients of working age being unemployed, 44% of
whom related this to poor health. In a more recent
Italian study [17], axSpA employment rates were slightly
lower than in the general population (53% vs 58%), 14%
of patients reported axSpA-related discrimination at work
and the proportion of patients receiving disability benefits
was nearly five times higher than that in the general popu-
lation (34% vs 7.3%). However, extrapolation of data be-
tween AS and axSpA and from one country to another is
challenging because of local influencing factors such as
local unemployment/disability benefit systems [18].
A number of factors have been found to be associated
with work disability and loss of productivity at work.
Unemployment is associated with older age, social de-
privation, longer disease duration, functional impairment
and depression. Absenteeism is associated with worse
disease activity and depression, while presenteeism is
associated with a wider range of factors including older
age, worse disease activity, poorer physical function,
lower quality of life, anxiety, depression [15] and a sense
of helplessness [19]. Correlations between increased
signs and symptoms of disease and reduced work prod-
uctivity suggest that treatments aimed at improving help-
lessness, reducing anxiety/depression and controlling
disease activity could also reduce work disability and
loss of productivity [15, 19, 20].
Frequency of psychological symptoms in
axSpA and their impact on patients’
overall well-being
Psychological distress, including symptoms of depression
and anxiety, is an important factor to consider when
determining outcomes and quality of life in patients with
axSpA. Some studies have described the close associ-
ation between mood and measures of self-reported
disease activity, functional status, educational achieve-
ment, deprivation, pain and HRQoL in AS [2128].
Psychological distress is frequently reported in patients
with a variety of rheumatic disorders, more commonly
than in the general population [29]. The reported preva-
lence of depression and anxiety in axSpA is extremely
wide, varying between 9 and 56%, and 19 and 60%, re-
spectively [2128, 30]. Anxiety and depression scores
were reported in one study to be similar in AS and in
non-radiographic axSpA [24].
Although historically underevaluated because of low
numbers of women in studies, recent publications have
indicated that women with AS have more depression
[21] and anxiety [22] than men with the condition. As in
the general population, social deprivation may affect the
psychological state of individuals with axSpA [23].
Disease activity scores (including BASDAI and ASDAS-
CRP) significantly correlate with both anxiety and depres-
sion in AS [2426, 28], with one study also reporting ESR,
a laboratory measure of inflammation, as an independent
risk factor for higher anxiety scores [26]. In the one axSpA
study to date to examine the relationship between psy-
chological distress and disease activity, only depression
(not anxiety) appears to be related to disease activity [24].
Decreased physical function and AS-related restricted
range of movement also appear to detrimentally influence
mood [2426]. Both poor disease activity and physical
function are also associated with wider psychological
characteristics such as passive coping strategies and a
sense of helplessness [27, 28].
Fatigue
Health economic burden, a major component of which is
fatigue, increases steeply with increasing disease activity
[31]. Estimates suggest that up to 66% of patients with AS
are affected by fatigue [32], comparable to the rate in
other long-term inflammatory conditions such as RA
[33]. The complex, multi-dimensional nature of fatigue
associated with a range of rheumatological conditions
has been distinguished from normal everyday tiredness
by frequency, persistence, unpredictability and failure to
be resolved by rest [34, 35]. Growing acknowledgment of
the relative importance of AS fatigue [36] has fuelled inter-
est in its treatment and management [37, 38], and high-
lighted the need for accurate and credible assessment
[38].
Current international guidance for AS fatigue assess-
ment is limited to a single item, the global assessment
of severity (BASDAI question 1) [39]. The complex nature
of fatigue experienced in AS means that limited assess-
ment potentially fails to identify patients at risk of fatigue-
related impairment.
The fatigue related to the inflammatory elements of
axSpA may be detrimentally affected by the fatigue from
concurrent pain syndromes such as FM [40], which is
more common in patients with AS than in the general
population. In comparison with a population prevalence
of 24% [41], a Brazilian study [42] reported a prevalence
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the observation of the high prevalence of FM in inflamma-
tory rheumatic diseases in general [41]. The presence of
FM alongside axSpA may influence patients’ perceptions
of pain, function and disease activity, and may distort re-
sponses to key patient-reported outcome measures such
as BASDAI and the BASFI.
HRQoL
HRQoL is a broad, multi-dimensional concept that usually
includes subjective evaluations of both positive and nega-
tive aspects of life. It may be defined as the ‘net conse-
quence of a disease and its treatment on a patient’s
perception of his or her ability to live a useful and fulfilling
life’ [43]. It is challenging to measure because quality of
life has a different meaning for nearly every individual and
every disease state. Although health is one of the import-
ant domains of overall quality of life, there are other
equally important aspects of life that can be affected by
illness, such as family life, social support, body image,
ability to work, housing, spirituality and socioeconomic
status [43].
Despite these challenges, HRQoL questions have
become an important component of public health surveil-
lance and are generally considered valid indicators of
unmet needs and intervention outcomes. The efficient
and cost-effective management of any disease requires
competing treatment regimens to be evaluated for their
ability to both control disease activity and improve the
quality of life of patients.
AS often has a significant impact upon an individual’s
HRQoL [44]; the magnitude of this is at least equivalent to
that seen in patients with other chronic conditions such as
diabetes, arthritis and hypertension [45]. Traditional meth-
ods of evaluation—with their focus on the locomotor
system, measures of impairment and disease activ-
ity—will inevitably fail to describe the extensive multi-di-
mensional issues associated with axSpA disease.
Given the typical age at onset of the disease and the
subsequent progression towards disability with, historic-
ally, few therapeutic alternatives, it is perhaps not surpris-
ing that patients with axSpA have had such diminished
HRQoL. As spinal mobility is progressively lost, or pain
levels escalate, difficulty in performing simple physical
routines places a huge burden on these patients that ex-
tends beyond the physical hardship and compromises the
patient’s social and psychological function. Reductions in
HRQoL are most pronounced in the more physical and
disease activity domains, but are also clearly evident in
the psychosocial domains: axSpA leads to changes in
mood or personality, low self-esteem, stigma of disease
and worry about the future, and adversely affects social
life and relationships with friends and family [46]. For ex-
ample, uncontrolled axSpA disease may threaten the abil-
ity of a young adult to remain in employment and hence
support their family both financially and emotionally [47]. It
may affect them physically, for instance by limiting the
amount of sport they can participate in and directly influ-
encing self-perceptions of success in achieving a trad-
itional gender role. Consequently, their ability to fulfil
their role as a partner, a parent and a member of society
is challenged.
Overall health and functioning
Recently, ASAS introduced the first AS-specific health
index (ASAS HI), which can be used to measure overall
functioning and health [48]. The index contains 17 patient-
rated items covering the whole range of International
Classification of Functioning, Disability and Health cate-
gories, including pain, emotional functions, sleep, sexual
functions, mobility, self-care and community life. Patients
are asked to respond ‘agree’ or ‘do not agree’ with a
statement in each category, resulting in a score from 0
to 17. Unlike the symptom-specific instruments described
above, ASAS HI captures whether problems are present in
different categories of functioning rather than the subject-
ive experience of those problems [48].
Therapy for AS
There is good evidence that treatment with many of the
licensed biologic therapies is associated with significant
improvements in all aspects of HRQoL, from disease ac-
tivity, pain and physical functioning to work stability, pa-
tients’ psychological health and global quality of life
[4954]. These important changes in the clinical manage-
ment of axSpA have resulted in the widespread use of
biologic therapies.
People with aggressive disease are offered such treat-
ments more commonly, and at an earlier stage in the dis-
ease course [55]. The evidence is clear that short-term
benefits can be considerable. However, there are also
short-term risks (e.g. increased vulnerability to infection),
and the long-term consequences of these treatments
(e.g. theoretical risk of malignancy) remain uncertain
[56]. This is of particular concern in AS/axSpA: those
who are offered biologics are often in relatively early adult-
hood, at a point when their disease is at its most severe
and their wider lives are characterized by change and un-
certainty, when they are confronted with a decision that
may have profound long-term consequences.
Shared decision-making
Healthcare professionals play an important role as
providers of information and advice for patients [57, 58].
However, treatment decisions are also influenced by inter-
actions with people outside the healthcare team [59, 60].
In considering lay influence, the research literature
focuses substantially on the significant other, often a
long-term partner or spouse [61, 62]. Given that people
are committing to a partner much later in life than in the
past [63, 64] and a growing proportion of younger adults
do not have a significant other, focusing exclusively on
this relationship as a source of influence or support for
decision-making is problematic.
Being clear who is involved in helping patients make
healthcare decisions is important in order to ensure every-
one involved has appropriate information. The healthcare
https://academic.oup.com/rheumatology vi31







atology/article-abstract/57/suppl_6/vi29/5184858 by Keele U
niversity user on 15 January 2019
team needs to foresee challenges and pre-empt potential
problems in order to tailor care and information effectively
to patients’ needs.
Conclusion
The wide-ranging impact of AS/axSpA on the individual
means that a holistic approach should be taken. Treating
the inflammation and presuming everything else will im-
prove is overly simplistic and runs the real risk of missing
disease impact on major areas of life, with the potential to
prevent patients managing and living successfully with
their disease. Adopting a patient-centred approach and
ensuring that the impact of AS/axSpA is considered
across the physical, psychological, vocational and social
spectrum, rather than maintaining a narrow focus on dis-
ease activity, should enhance care and achieve real-life
improvements for patients.
Acknowledgements
Editorial assistance was provided by Succinct Medical
Communications, and funded by Novartis
Pharmaceuticals UK Ltd.
Supplement: Novartis has fully funded the production
and printing of this supplement. Novartis suggested the
topic and authors and reviewed the content to ensure
compliance with appropriate regulations. Content was
peer reviewed and final editorial control remained with
the authors.
Funding: No specific funding was received from any
bodies in the public, commercial or not-for-profit sectors
to carry out the work on this manuscript.
Disclosure statement: J.P. has received educational hon-
oraria from AbbVie.
References
1 van Tubergen A. The changing clinical picture and epi-
demiology of spondyloarthritis. Nat Rev Rheumatol
2015;11:1108.
2 Rudwaleit M, van der Heijde D, Landewe´ R et al. The de-
velopment of Assessment of SpondyloArthritis interna-
tional Society classification criteria for axial
spondyloarthritis (part II): validation and final selection.
Ann Rheum Dis 2009;68:77783.
3 Kiltz U, Baraliakos X, Karakostas P et al. Do patients with
non-radiographic axial spondylarthritis differ from patients
with ankylosing spondylitis? Arthritis Care Res
2012;64:141522.
4 Rudwaleit M, Haibel H, Baraliakos X et al. The early dis-
ease stage in axial spondylarthritis: results from the
German Spondyloarthritis Inception Cohort. Arthritis
Rheum 2009;60:71727.
5 Wallis D, Haroon N, Ayearst R, Carty A, Inman RD.
Ankylosing spondylitis and nonradiographic axial spon-
dyloarthritis: part of a common spectrum or distinct dis-
eases? J Rheumatol 2013;40:203841.
6 Boonen A, Sieper J, van der Heijde D et al. The burden of
non-radiographic axial spondyloarthritis. Semin Arthritis
Rheum 2015;44:55662.
7 Boonen A. A review of work-participation, cost-of-illness
and cost-effectiveness studies in ankylosing spondylitis.
Nat Clin Pract Rheumatol 2006;2:54653.
8 Braun J, Bollow M, Remlinger G et al. Prevalence of
spondylarthropathies in HLA-B27 positive and negative
blood donors. Arthritis Rheum 1998;41:5867.
9 Gran JT, Husby G, Hordvik M. Prevalence of ankylosing
spondylitis in males and females in a young middle-aged
population of Tromsø, northern Norway. Ann Rheum Dis
1985;44:35967.
10 Karkucak M, Cakirbay H, Capkin E et al. The prevalence of
ankylosing spondylitis in the eastern black sea region of
Turkey. Eur J Gen Med 2011;8:405.
11 Dai S-M, Han X-H, Zhao D-B et al. Prevalence of rheum-
atic symptoms, rheumatoid arthritis, ankylosing spondyl-
itis, and gout in Shanghai, China: a COPCORD study.
J Rheumatol 2003;30:224551.
12 Dagfinrud H, Kjeken I, Mowinckel P, Hagen KB, Kvien TK.
Impact of functional impairment in ankylosing spondylitis:
impairment, activity limitation, and participation restric-
tions. J Rheumatol 2005;32:51623.
13 Singh JA, Strand V. Spondyloarthritis is associated with
poor function and physical health-related quality of life.
J Rheumatol 2009;36:101220.
14 Haglund E, Bremander A, Bergman S, Jacobsson LTH,
Petersson IF. Work productivity in a population-based
cohort of patients with spondyloarthritis. Rheumatology
(Oxford) 2013;52:170814.
15 Healey EL, Haywood KL, Jordan KP, Garratt A, Packham
JC. Impact of ankylosing spondylitis on work in patients
across the UK. Scand J Rheumatol 2011;40:3440.
16 Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D.
Validity, reliability and responsiveness of the Work
Productivity and Activity Impairment Questionnaire in anky-
losing spondylitis. Rheumatology (Oxford) 2010;49:8129.
17 Ramonda R, Marchesoni A, Carletto A et al. Patient-re-
ported impact of spondyloarthritis on work disability and
working life: the ATLANTIS survey. Arthritis Res Ther
2016;18:78.
18 Boonen A, van der Heijde D, Landewe´ R et al. Work status
and productivity costs due to ankylosing spondylitis:
comparison of three European countries. Ann Rheum Dis
2002;61:42937.
19 Gordeev VS, Maksymowych WP, Schachna L, Boonen A.
Understanding presenteeism in patients with ankylosing
spondylitis: contributing factors and association with sick
leave. Arthritis Care Res 2014;66:91624.
20 Prince DS, McGuigan LE, McGirr EE. Working life and
physical activity in ankylosing spondylitis pre and post
anti-tumor necrosis factor-alpha therapy. Int J Rheum Dis
2014;17:16572.
21 Barlow JH, Macey SJ, Struthers GR. Gender, depression,
and ankylosing spondylitis. Arthritis Care Res
1993;6:4551.
22 Healey EL, Haywood KL, Jordan KP, Garratt A, Packham
JC. Prevalence, gender differences and factors asso-









atology/article-abstract/57/suppl_6/vi29/5184858 by Keele U
niversity user on 15 January 2019
patients with ankylosing spondylitis from across the
United Kingdom. Rheumatology (Oxford) 2008;47:ii78.
23 Healey EL, Haywood KL, Jordan KP, Garratt AM,
Packham JC. Disease severity in ankylosing spondylitis:
variation by region and local area deprivation.
J Rheumatol 2010;37:6338.
24 Kilic G, Kilic E, Ozgocmen S. Relationship between psy-
chiatric status, self-reported outcome measures, and
clinical parameters in axial spondyloarthritis. Medicine
2014;93:e337.
25 Martindale J, Smith J, Sutton CJ et al. Disease and psy-
chological status in ankylosing spondylitis. Rheumatology
(Oxford) 2006;45:128893.
26 Baysal O, Durmus¸ B, Ersoy Y et al. Relationship between
psychological status and disease activity and quality of
life in ankylosing spondylitis. Rheumatol Int 2011;31:
795800.
27 Brionez TF, Assassi S, Reveille JD et al. Psychological
correlates of self-reported functional limitation in patients
with ankylosing spondylitis. Arthritis Res Ther
2009;11:R182.
28 Brionez TF, Assassi S, Reveille JD et al. Psychological
correlates of self-reported disease activity in ankylosing
spondylitis. J Rheumatol 2010;37:82934.
29 Murphy LB, Sacks JJ, Brady TJ, Hootman JM, Chapman
DP. Anxiety and depression among US adults with arth-
ritis: prevalence and correlates. Arthritis Care Res
2012;64:96876.
30 Hakkou J, Rostom S, Aissaoui N et al. Psychological
status in Moroccan patients with ankylosing spondylitis
and its relationships with disease parameters and quality
of life. J Clin Rheumatol Pract Rep Rheum Musculoskelet
Dis 2011;17:4248.
31 Rafia R, Ara R, Packham J, Haywood KL, Healey E.
Healthcare costs and productivity losses directly attribut-
able to ankylosing spondylitis. Clin Exp Rheumatol
2012;30:24653.
32 Aissaoui N, Rostom S, Hakkou J et al. Fatigue in patients
with ankylosing spondylitis: prevalence and relationships
with disease-specific variables, psychological status, and
sleep disturbance. Rheumatol Int 2012;32:211724.
33 Wolfe F, Hawley DJ, Wilson K. The prevalence and
meaning of fatigue in rheumatic disease. J Rheumatol
1996;23:140717.
34 Hewlett S, Cockshott Z, Byron M et al. Patients’ percep-
tions of fatigue in rheumatoid arthritis: overwhelming, un-
controllable, ignored. Arthritis Rheum 2005;53:697702.
35 Cleanthous S, Tyagi M, Isenberg DA, Newman SP. What
do we know about self-reported fatigue in systemic lupus
erythematosus? Lupus 2012;21:46576.
36 Heiberg T, Lie E, van der Heijde D, Kvien TK. Sleep
problems are of higher priority for improvement for pa-
tients with ankylosing spondylitis than for patients with
other inflammatory arthropathies. Ann Rheum Dis
2011;70:8723.
37 Davies H, Brophy S, Irvine E et al. Self-managing fatigue in
ankylosing spondylitis and potential interventions: a
qualitative study of patients’ perspectives. Rheumatology
(Oxford) 2012;51:iii89.
38 Farren W, Goodacre L, Stigant M. Fatigue in ankylosing
spondylitis: causes, consequences and self-management.
Musculoskeletal Care 2013;11:3950.
39 Sieper J, Rudwaleit M, Baraliakos X et al. The Assessment
of SpondyloArthritis international Society (ASAS) hand-
book: a guide to assess spondyloarthritis. Ann Rheum Dis
2009;68(Suppl 2):ii144.
40 Salaffi F, De Angelis R et al. Fibromyalgia in patients with
axial spondyloarthritis: epidemiological profile and effect
on measures of disease activity. Rheumatol Int
2014;34:110310.
41 Clauw DJ, Katz P. The overlap between fibromyalgia and
inflammatory rheumatic disease: when and why does it
occur? J Clin Rheumatol 1995;1:33542.
42 Azevedo VF, Paiva Edos S, Felippe LRH, Moreira RA.
Occurrence of fibromyalgia in patients with ankylosing
spondylitis. Rev Bras Reumatol 2010;50:64650.
43 Ward MM. Quality of life in patients with ankylosing
spondylitis. Rheum Dis Clin North Am 1998;24:81527.
44 Haywood KL, Garratt AM, Jordan KP, Healey EL,
Packham JC. Evaluation of ankylosing spondylitis quality
of life (EASi-QoL): reliability and validity of a new patient-
reported outcome measure. J Rheumatol
2010;37:21009.
45 Davis JC, van der Heijde D, Dougados M, Woolley JM.
Reductions in health-related quality of life in patients with
ankylosing spondylitis and improvements with etanercept
therapy. AC&R 2005;53:494501.
46 Hamilton-West KE, Quine L. Living with ankylosing spon-
dylitis: the patient’s perspective. J Health Psychol
2009;14:82030.
47 Madsen M, Jensen KV, Esbensen BA. Men’s experiences
of living with ankylosing spondylitis: a qualitative study.
Musculoskeletal Care 2015;13:3141.
48 Kiltz U, van der Heijde D, Boonen A et al. Development of a
health index in patients with ankylosing spondylitis (ASAS
HI): final result of a global initiative based on the ICF guided
by ASAS. Ann Rheum Dis 2015;74:8305.
49 Ertenli I, Ozer S, Kiraz S et al. Infliximab, a TNF-a antag-
onist treatment in patients with ankylosing spondylitis: the
impact on depression, anxiety and quality of life level.
Rheumatol Int 2012;32:32330.
50 van der Heijde DM, Revicki DA, Gooch KL et al. Physical
function, disease activity, and health-related quality-of-life
outcomes after 3 years of adalimumab treatment in pa-
tients with ankylosing spondylitis. Arthritis Res Ther
2009;11:R124.
51 van der Heijde D, Deodhar A, Braun J et al. The effect of
golimumab therapy on disease activity and health-related
quality of life in patients with ankylosing spondylitis: 2-year
results of the GO-RAISE trial. J Rheumatol
2014;41:1095103.
52 Boonen A, Patel V, Traina S et al. Rapid and sustained
improvement in health-related quality of life and utility for
72 weeks in patients with ankylosing spondylitis receiving
etanercept. J Rheumatol 2008;35:6627.
53 Baeten D, Sieper J, Braun J et al. Secukinumab, an
interleukin-17a inhibitor, in ankylosing spondylitis. N Engl J
Med 2015;373:253448.
https://academic.oup.com/rheumatology vi33







atology/article-abstract/57/suppl_6/vi29/5184858 by Keele U
niversity user on 15 January 2019
54 Keat AC, Gaffney K, Gilbert AK, Harris C, Leeder J.
Influence of biologic therapy on return to work in people
with work disability due to ankylosing spondylitis.
Rheumatology (Oxford) 2008;47:4813.
55 Ruth NM, Passo MH. Juvenile idiopathic arthritis: man-
agement and therapeutic options. Ther Adv Musculoskelet
Dis 2012;4:99110.
56 Lipstein EA, Muething KA, Dodds CM, Britto MT. ‘‘I’m the
one taking it’’: adolescent participation in chronic disease
treatment decisions. J Adolesc Health 2013;53:2539.
57 Edwards A, Elwyn G. Inside the black box of shared de-
cision making: distinguishing between the process of in-
volvement and who makes the decision. Health Expect
2006;9:30720.
58 Arkell P, Ryan S, Brownfield A, Cadwgan A, Packham J.
Patient experiences, attitudes and expectations towards
receiving information about anti-TNF medication‘‘It could
give me two heads and I’d still try it!’’. BMC Musculoskelet
Disord 2013;14:165.
59 Ohle´n J, Balneaves LG, Bottorff JL, Brazier ASA. The in-
fluence of significant others in complementary and alter-
native medicine decisions by cancer patients. Soc Sci
Med 2006;63:162536.
60 Rapley T. Distributed decision making: the anatomy
of decisions-in-action. Sociol Health Illn
2008;30:42944.
61 Mann C, Dieppe P. Different patterns of illness-related
interaction in couples coping with rheumatoid arthritis.
Arthritis Rheum 2006;55:27986.
62 Matheson L, Harcourt D, Hewlett S. ‘‘Your whole life, your
whole world, it changes’’: partners’ experiences of living
with rheumatoid arthritis. Musculoskeletal Care
2010;8:4654.
63 Office for National Statistics. Marriages in England and
Wales (Provisional). 2011. UK: ONS, 2013.
64 Beaujouan E, Nı´ Bhrolcha´in M. Cohabitation and mar-










atology/article-abstract/57/suppl_6/vi29/5184858 by Keele U
niversity user on 15 January 2019
